Abacavir/dolutegravir/lamivudine

Abacavir/dolutegravir/lamivudine
Combination of
Abacavirnucleoside analog reverse transcriptase inhibitor
Dolutegravirintegrase inhibitor
Lamivudinenucleoside analog reverse transcriptase inhibitor
Clinical data
Trade namesTriumeq, Triumeq PD
AHFS/Drugs.comMonograph
MedlinePlusa617015
License data
Pregnancy
category
  • AU: B3
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
  • none
KEGG

Abacavir/dolutegravir/lamivudine, sold under the brand name Triumeq among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.[3] It is a combination of three medications with different and complementary mechanisms of action: abacavir (reverse transcriptase inhibitor), dolutegravir (integrase inhibitor) and lamivudine (nucleoside analog reverse transcriptase inhibitor).[3]

The medication was developed by ViiV Healthcare and was approved for use in the United States and in the European Union in 2014.[4][5][6]

Abacavir is a nucleotide reverse transcriptase inhibitor.[3] Specifically, abacavir is a guanosine analogue that interferes with HIV viral RNA-dependent DNA polymerase, ultimately resulting in inhibition of replication of HIV. Dolutegravir inhibits the HIV replication cycle by binding to the integrase active site and inhibiting the strand transfer step of HIV-1 DNA integration. Lamivudine is a cytosine analogue that inhibits HIV reverse transcription by terminating the viral DNA chain.[7]

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved October 22, 2023.
  2. ^ "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. October 14, 2020. Retrieved April 17, 2024.
  3. ^ a b c d "Triumeq - abacavir sulfate, dolutegravir sodium, lamivudine tablet, film coated; Triumeq PD - abacavir sulfate, dolutegravir sodium, lamivudine kit". DailyMed. April 18, 2024. Retrieved June 21, 2024.
  4. ^ a b "Triumeq EPAR". European Medicines Agency (EMA). October 15, 2014. Retrieved April 7, 2020.
  5. ^ "Triumeq (abacavir sulfate, dolutegravir, and lamivudine), Fixed-Dose Combination Tablets". U.S. Food and Drug Administration (FDA). August 11, 2015. Retrieved April 7, 2020.
  6. ^ "FDA Approves Triumeq". drugs.com. August 22, 2014.
  7. ^ "Login". Lexicomp. Retrieved December 10, 2015.